By Ian Walker

Shares of GENinCode rose 17% after the company said that it has filed a premarket notification with the U.S. Food and Drug Administration for its coronary heart disease risk assessment test kit, Cardio inCode-Score.

Shares at 1106 GMT were up 2.0 pence at 13.50 pence.

The London-listed predictive genetics company said Wednesday that approval will enable the expansion and commercial distribution of the device in the U.S.

It expects to receive FDA approval for the device over the next six months.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

August 16, 2023 07:26 ET (11:26 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Genincode (LSE:GENI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Genincode.
Genincode (LSE:GENI)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Genincode.